tldrdailynews.com logo

Wegovy shows early momentum with 3,071 U.S. prescriptions in launch days

1 min read
Source: Reuters
Wegovy shows early momentum with 3,071 U.S. prescriptions in launch days
Photo: Reuters
TL;DR

Novo Nordisk’s oral Wegovy drew 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by analysts show, indicating early momentum in a competitive weight‑loss market as the company vies with Eli Lilly. The figure counts retail prescriptions only (not online NovoCare Pharmacy fillings), so actual demand is likely higher.

Topics:businesshealthcare-and-pharmaceuticals#health#healthcare-and-pharmaceuticals#novo-nordisk#obesity#pharmaceuticals#wegovy
Share this article
  1. Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch  Reuters
  2. Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch  CNBC
  3. Lubbock Doctor compares weight loss injections to new pills  KCBD
  4. Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus  Yahoo Finance
  5. Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030  Reuters

Want the full story? Read the original reporting

Read on Reuters